Company

Disruptive precision medicine technology conquering inflammation and diabetes

Leadership Team

Raquel Hontecillas, DVM-PhD

Chief Scientific Officer

• 17 years of translational experience in the biotech industry focusing on infectious, immune-mediated, and metabolic diseases.
• Identified and validated the role of the Lanthionine Synthetase C like 2 (LANCL2) pathway as a key therapeutic target for diabetes and inflammatory bowel disease.
• Expanded Biotherapeutics Inc.‘s product pipeline with other novel targets and therapeutics.
• Published over 100 peer-reviewed papers, 5 patents and manages an R&D portfolio of $15 million.
• Please email me at rmagarzo@biotherapeuticsinc.com